Quantcast
Last updated on April 17, 2014 at 16:43 EDT

Latest Long QT syndrome Stories

2011-10-18 07:30:00

ALISO VIEJO, Calif., Oct. 18, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from clinical research activities will be highlighted at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam, the Netherlands. ECTRIMS is considered the world's largest annual international conference devoted to basic and clinical research in multiple sclerosis. Following are...

2011-08-11 07:30:00

ALISO VIEJO, Calif., Aug. 11, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has filed lawsuits in the U.S. District Court for the District of Delaware against Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc (collectively "Par") and Actavis South Atlantic LLC and Actavis, Inc. (collectively "Actavis"). The lawsuits were filed in response to Abbreviated New Drug Applications ("ANDAs") filed by Par and Actavis. In their...

2011-07-26 07:30:00

ALISO VIEJO, Calif., July 26, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced several positive developments regarding its anticipated European regulatory filing of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules for the treatment of pseudobulbar affect (PBA). On July 22, 2011, company officials met with the European Medicines Agency (EMA) to discuss plans for filing a marketing authorization application (MAA)...

2011-07-14 15:17:23

The human genome encodes 243 voltage-gated ion channels. Mutations in calcium channels can cause severe inherited diseases such as migraine, night blindness, autism spectrum disorders and Timothy syndrome, which leads to severe cardiovascular disorders. Katrin Depil and Anna Stary-Weinzinger together with colleagues from the Department of Pharmacology and Toxicology, University of Vienna analyzed changes in molecular organization of calcium channels caused by Timothy syndrome mutations....

2011-07-01 07:30:00

ALISO VIEJO, Calif., July 1, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) website indicates that an Abbreviated New Drug Application (ANDA) for a generic version of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules was submitted on March 7, 2011. The company received Paragraph IV certification notices on June 30, 2011. Avanir intends to vigorously enforce its...

2011-05-16 07:30:00

ALISO VIEJO, Calif., May 16, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from a number of clinical research activities will be highlighted at the 164th Annual Meeting of the American Psychiatric Association (APA) taking place in Honolulu, HI, at the Hawaii Convention Center. Following are details about the data presentations: Title: The Safety of Dextromethorphan/Quinidine in Clinical Trial Participants Taking Selective Serotonin Reuptake...

2011-05-04 09:42:00

OMAHA, Neb., May 4, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) announced a significant enhancement to its FAMILION Brugada Syndrome (BrS) test panel at the 2011 Heart Rhythm Society meeting in San Francisco. The expanded panel includes analysis of 9 genes and broadens the test indication to include other J-wave syndromes, including Early Repolarization Syndrome. "The addition of two newly identified J-wave syndrome genes, KCND3 and KCNJ8, reflects Transgenomic's commitment...

2011-04-21 14:50:46

TAU pioneers new test for "sudden death syndrome" in young athletes When a high school athlete drops dead, the rare but fatal condition called "sudden death syndrome" dominates the headlines. For reasons that remain a mystery to scientists, some young athletes "” especially young males "” begin to experience an unusual heart arrhythmia. With over-exertion, their hearts stop pumping, leading to sudden death. Until now, screening for the hard-to-detect syndrome has been...

2011-04-11 07:30:00

ALISO VIEJO, Calif., April 11, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of William (Bill) Sibold to the position of senior vice president and chief commercial officer. In this newly created role, Mr. Sibold will be responsible for leading all of the company's commercial activities. "Bill has an outstanding track record of success in biopharmaceutical sales and marketing," said Keith A. Katkin, president and CEO of Avanir. "I am...

2011-04-07 15:05:00

ALISO VIEJO, Calif., April 7, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from a number of clinical research activities will be highlighted at the 63rd Annual Meeting of the American Academy of Neurology (AAN), taking place in Honolulu, HI, at the Hawaii Convention Center from April 9 through 16, 2011. Following are details about the data presentations: Title: Burden of Pseudobulbar Affect on Social Function and Quality of...